On Thursday, Shares of eBay Inc. (NASDAQ:EBAY), gained 2.36% to $61.85.
eBay Inc., declared “Hot Deals for Hot Days,” a new experience that gives shoppers amazing deals on must-have items tied to the weather: the hotter the temperatures, the hotter the deals. Startning the Fourth of July, eBay will offer designer sunglasses at a deep discount that mirrors the forecasted high temperature1 of the day – if forecasted to be 85 degrees in Montauk, shoppers will get 85 percent off their new sunglasses.
Timed to summer’s biggest holiday, shoppers are invited to visit eBay’s “Hot Deals for Hot Days” custom Airstream to browse and buy new Ray-Bans and Michael Kors sunglasses, while cooling down with iced treats from Brooklyn’s People’s Pops. The eBay Deals Airstream will make its debut in the Hamptons on July 4th and then travel to New York City on July 7 and 8.
eBay Inc. operates as a technology company that enables commerce and payments on behalf of users, merchants, retailers, and brands of various sizes in the United States and internationally. It operates in three segments: Marketplaces, Payments, and Enterprise.
Shares of The Medicines Company (NASDAQ:MDCO), inclined 10.37% to $31.28, during its last trading session.
The Medicines Company, declared the approval of KENGREAL™ (cangrelor) by the U.S. Food and Drug Administration (FDA) as an adjunctive therapy to percutaneous coronary intervention (PCI) for reducing periprocedural thrombotic events in patients who have not been treated with a P2Y12 inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor (GPI).
The Medicines Company anticipates KENGREAL to be accessible in the U.S. in July.
KENGREAL is the first and only intravenous, reversible P2Y12 platelet inhibitor with an immediate onset of action for patients undergoing PCI that, in clinical trials, has been shown to reduce the risk of periprocedural thrombotic events, counting myocardial infarction, stent thrombosis, and repeat coronary revascularization.
The Medicines Company provides medicines for patients in acute and intensive care hospitals worldwide. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for use in patients undergoing percutaneous coronary intervention; Cleviprex, an intravenous small molecule calcium channel blocker for blood pressure reduction.
Finally, Allison Transmission Holdings, Inc. (NYSE:ALSN), ended its last trade with -0.41% loss, and closed at $29.14.
On June 19, Allison Transmission Holdings Inc. declared that it has been working with the U.S. Environmental Protection Agency (EPA) and National Highway Traffic Safety Administration (NHTSA) as they consider revisions to the ‘Phase I’ Model Year 2014-2018 rule regarding fuel efficiency and greenhouse gas emission (GHG) standards for medium and heavy-duty vehicles. The revisions would potentially extend the Phase I program into the middle of the next decade.
“Given the complexity of the medium- and heavy-duty commercial vehicle manufacturing sector, and the wide range of vehicles and vehicle configurations involved, we are encouraged that EPA and NHTSA have been willing to engage with Allison and other companies to review technical issues and conduct additional testing,” said Deborah Gordon, executive director of regulatory issues and hybrid programs for Allison Transmission. “We anticipate ongoing to work with both agencies as they move forward with their ‘Phase II’ rulemaking effort.”
Allison Transmission Holdings, Inc., together with its auxiliaries, designs, manufactures, and sells commercial and defense fully-automatic transmissions for medium- and heavy-duty commercial vehicles, and medium- and heavy-tactical U.S. defense vehicles.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
